TRUST: This study aims to evaluate the toxicity and quality of life outcomes associated with urethra-sparing prostate stereotactic ablative radiotherapy (SABR) for intermediate risk prostate cancerEfficacy of toxicity reduction with urethra sparing stereotactic ablative body radiation therapy for prostate cancer, assessing toxicities and quality of life in patients with intermediate risk prostate cancer.

Trial purpose

Cancer treatment

Tumor type

Genitourinary

Age

18+

Trial acronym

TRUST

Summary

You may be eligible to join this study if you are aged 18 years or above and have intermediate risk prostate cancer.

Traditional radiotherapy for intermediate risk prostate cancer typically involves 4 weeks of daily treatment. Recent studies have shown that using fewer but larger doses of radiation, i.e. 5-treatment stereotactic ablative radiotherapy (SABR), is just as effective and safe, and this has now become one of the standard radiation schedule options for men with intermediate risk prostate cancer.

The question then is whether we can further reduce treatment-related toxicities while maintaining cancer control. 

In this Australian Phase II trial of urethra-sparing prostate SABR, researchers aim to evaluate the efficacy, toxicity, and quality of life outcomes of this treatment.

Eligible participants will receive SABR to the prostate, delivered in 5 fractions, 2-3 fractions per week. 

Conditions

This trial is treating people with intermediate risk prostate cancer